Market Currents
Oral drugs for treating hepatitis C from Merck (MRK) and Abbott Labs (ABT) were highly effective...
-
Sunday, November 11, 2012, 3:19 AM ETOral drugs for treating hepatitis C from Merck (MRK) and Abbott Labs (ABT) were highly effective in Phase II trials. A regimen that included Merck's MK-5172 suppressed the virus in most patients and appears to be better than the company's Victrelis. Merck now intends to conduct new studies, while Abbott has already started Phase III trials of a regimen of three of its treatments - ABT-450, boosting agent ritonavir (ABT-267) and ABT-333.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
